Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

H.I. Andtbacka, Robert; A. Collichio, Frances; J. Harrington, Kevin; R. Middleton, Mark; Downey, Gerald; Öhrling, Katarina; L. Kaufman, Howard

doi:10.1186/s40425-019-0623-z

Public

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Published in Journal for ImmunoTherapy of Cancer • Jun 6, 2019

Authors:

Robert H.I. Andtbacka

Frances A. Collichio

Kevin J. Harrington

Abstract

BACKGROUND: Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB-IVM1c melanoma. METHODS: Patients were randomized ...

Subject

Medicine

Oncolytic virus

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!